Conserved Salt-bridge between the Nand C-Terminal Heptad Repeat Regions of HIV-1 gp 41 Core Structure Is Critical for Virus Entry and Inhibition

[1]  H. Garg,et al.  HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. , 2008, Vaccine.

[2]  Yonghong Xiao,et al.  Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor* , 2008, Journal of Biological Chemistry.

[3]  Hong Lu,et al.  Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors , 2008, Journal of Virology.

[4]  W. Alvord,et al.  A Covalent Inhibitor Targeting an Intermediate Conformation of the Fusogenic Subunit of the HIV-1 Envelope Complex* , 2007, Journal of Biological Chemistry.

[5]  Y. Shai,et al.  Demonstrating the C‐terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Debnath,et al.  Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain Is Critical for Six-helix Bundle Stability and Virus Entry* , 2007, Journal of Biological Chemistry.

[7]  Amalio Telenti,et al.  HIV entry inhibitors , 2007, The Lancet.

[8]  K. Taylor,et al.  AIDS virus envelope spike structure. , 2007, Current opinion in structural biology.

[9]  Shibo Jiang,et al.  HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains , 2007, Journal of Biological Chemistry.

[10]  Shibo Jiang,et al.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. , 2007, Current pharmaceutical design.

[11]  Y. Shai,et al.  Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. , 2006, Journal of molecular biology.

[12]  Y. Shai,et al.  Characterization of the HIV N-terminal Fusion Peptide-containing Region in Context of Key gp41 Fusion Conformations* , 2006, Journal of Biological Chemistry.

[13]  A. Debnath.  Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1 , 2006, Expert opinion on investigational drugs.

[14]  Robert Blumenthal,et al.  Structurally Altered Peptides Reveal an Important Role for N-terminal Heptad Repeat Binding and Stability in the Inhibitory Action of HIV-1 Peptide DP178* , 2006, Journal of Biological Chemistry.

[15]  C. Bewley,et al.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. , 2005, Biochemistry.

[16]  Michael D. Miller,et al.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  I. Cohen,et al.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. , 2005, The Journal of clinical investigation.

[18]  Shibo Jiang,et al.  Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120* , 2005, Journal of Biological Chemistry.

[19]  A. Molla,et al.  Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. , 2004, Virology.

[20]  A. Debnath,et al.  N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion , 2004, Antimicrobial Agents and Chemotherapy.

[21]  Y. Shai,et al.  How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. , 2003, Journal of molecular biology.

[22]  Yuxian He,et al.  Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. , 2003, Vaccine.

[23]  C. Weiss.  HIV-1 gp41: mediator of fusion and target for inhibition. , 2003, AIDS reviews.

[24]  Shibo Jiang,et al.  Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors , 2003, Peptides.

[25]  S. A. Gallo,et al.  The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.

[26]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[27]  M. Lawrence,et al.  The structural biology of type I viral membrane fusion , 2003, Nature Reviews Molecular Cell Biology.

[28]  Joel E Gallant,et al.  A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy , 2003, AIDS.

[29]  M. Matsuoka,et al.  Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. , 2002, Angewandte Chemie.

[30]  Min Lu,et al.  Genetic Evidence that Interhelical Packing Interactions in the gp41 Core Are Critical for Transition of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein to the Fusion-Active State , 2002, Journal of Virology.

[31]  Min Lu,et al.  Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. , 2002, Biochemistry.

[32]  Min Lu,et al.  Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis , 2001, Journal of Virology.

[33]  M. Steinmetz,et al.  An Intrahelical Salt Bridge within the Trigger Site Stabilizes the GCN4 Leucine Zipper* , 2001, The Journal of Biological Chemistry.

[34]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[35]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[36]  C. Weiss,et al.  Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41 , 2000, Journal of Virology.

[37]  H. Ji,et al.  Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core. , 2000, Biochemistry.

[38]  J. Liu,et al.  Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. , 1999, Biochemistry.

[39]  Min Lu,et al.  Interactions between HIV-1 gp41 Core and Detergents and Their Implications for Membrane Fusion* , 1999, The Journal of Biological Chemistry.

[40]  Min Lu,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion , 1999, Journal of Virology.

[41]  A. Debnath,et al.  A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. , 1999, Journal of virological methods.

[42]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Weiss,et al.  Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41 , 1998, Journal of Virology.

[44]  Min Lu,et al.  A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein , 1998, Journal of Virology.

[45]  N. Kallenbach,et al.  Surface salt bridges stabilize the GCN4 leucine zipper , 1998, Protein science : a publication of the Protein Society.

[46]  A. Gronenborn,et al.  Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.

[47]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[48]  P S Kim,et al.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Chuang,et al.  Mutations in the Leucine Zipper-Like Heptad Repeat Sequence of Human Immunodeficiency Virus Type 1 gp41 Dominantly Interfere with Wild-Type Virus Infectivity , 1998, Journal of Virology.

[50]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[51]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[52]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[53]  P. S. Kim,et al.  A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. , 1997, Journal of biomolecular structure & dynamics.

[54]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[56]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[57]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[58]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[59]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[60]  C. N. Lee,et al.  Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein , 1993, Journal of virology.

[61]  J. Sodroski,et al.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.

[62]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[63]  S. Jiang,et al.  Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [published erratum appears in J Exp Med 1992 Feb 1;175(2):621] , 1991, The Journal of experimental medicine.

[64]  J. Moore,et al.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization , 1991, Journal of virology.

[65]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[66]  P. Earl,et al.  Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain , 1990, Journal of virology.

[67]  P. Earl,et al.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Y H Chen,et al.  Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. , 1974, Biochemistry.

[69]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.